drugset / Trial / NCT02542215

Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy

NCT02542215 ↗

Phase 2 Terminated 47 enrolled Sucampo Pharma Americas, LLC
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Treatment for head and neck cancer often involves a combination of chemotherapy and radiation. One of the unfortunate consequences of standard care for head and neck cancer is the development of painful mouth sores, known as oral mucositis. This study will evaluate the use of cobiprostone spray to prevent oral mucositis, when given for the duration of radiation and chemotherapy (RT/CT) standard care.

Timeline

Start
2015-06
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cobiprostone Small molecule 30 ug Oral

Indications